as 07-26-2024 4:00pm EST
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Founded: | N/A | Country: | France |
Employees: | N/A | City: | N/A |
Market Cap: | 123.7B | IPO Year: | N/A |
Target Price: | $55.00 | AVG Volume (30 days): | 2.4M |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | Dividend Payout Frequency: | Annual | |
EPS: | 1.83 | EPS Growth: | -36.48 |
52 Week Low/High: | $42.63 - $55.72 | Next Earning Date: | 07-25-2024 |
Revenue: | $50,964,516,129 | Revenue Growth: | 12.75% |
Revenue Growth (this year): | 1.84% | Revenue Growth (next year): | 6.95% |
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
CNW Group
13 hours ago
Zacks
14 hours ago
Argus Research
17 hours ago
Argus Research
17 hours ago
Investor's Business Daily
a day ago
Morningstar Research
a day ago
Motley Fool
a day ago
CNW Group
a day ago
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.